The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Aerovate Therapeutics, Inc. | Common Stock | 008064107 | 27,672,609 | 2,039,249 | SH | SOLE | 2,039,249 | 0 | 0 | ||
Akero Therapeutics, Inc. | Common Stock | 00973Y108 | 18,170,915 | 359,251 | SH | SOLE | 359,251 | 0 | 0 | ||
AvroBio, Inc. | Common Stock | 05455M100 | 6,993,727 | 4,541,381 | SH | SOLE | 4,541,381 | 0 | 0 | ||
Day One Biopharmaceuticals, Inc. | Common Stock | 23954D109 | 93,354,994 | 7,608,394 | SH | SOLE | 7,608,394 | 0 | 0 | ||
Dianthus Therapeutics, Inc. | Common Stock | 252828108 | 3,239,503 | 236,979 | SH | SOLE | 236,979 | 0 | 0 | ||
Disc Medicine, Inc. | Common Stock | 254604101 | 128,975,838 | 2,745,335 | SH | SOLE | 2,745,335 | 0 | 0 | ||
Dyne Therapeutics, Inc. | Common Stock | 26818M108 | 88,573,623 | 9,885,449 | SH | SOLE | 9,885,449 | 0 | 0 | ||
Generation Bio, Co. | Common Stock | 37148K100 | 31,379,244 | 8,279,484 | SH | SOLE | 8,279,484 | 0 | 0 | ||
Ikena Oncology, Inc. | Common Stock | 45175G108 | 21,728,711 | 5,018,178 | SH | SOLE | 5,018,178 | 0 | 0 | ||
Kymera Therapeutics, Inc. | Common Stock | 501575104 | 81,429,842 | 5,858,262 | SH | SOLE | 5,858,262 | 0 | 0 | ||
Replimune Group, Inc. | Common Stock | 76029N106 | 35,901,913 | 2,098,300 | SH | SOLE | 2,098,300 | 0 | 0 | ||
Spero Therapeutics, Inc. | Common Stock | 84833T103 | 1,226,260 | 1,013,438 | SH | SOLE | 1,013,438 | 0 | 0 | ||
Third Harmonic Bio, Inc. | Common Stock | 88427A107 | 69,701,219 | 10,907,859 | SH | SOLE | 10,907,859 | 0 | 0 | ||
Vigil Neuroscience, Inc. | Common Stock | 92673K108 | 31,460,750 | 5,836,874 | SH | SOLE | 5,836,874 | 0 | 0 | ||
Xilio Therapeutics, Inc. | Common Stock | 98422T100 | 5,822,216 | 2,759,344 | SH | SOLE | 2,759,344 | 0 | 0 |